Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Predicting frequent COPD exacerbations using primary care data

Authors Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB

Received 12 August 2015

Accepted for publication 19 September 2015

Published 9 November 2015 Volume 2015:10(1) Pages 2439—2450

DOI https://doi.org/10.2147/COPD.S94259

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Marjan Kerkhof,1 Daryl Freeman,2 Rupert Jones,3 Alison Chisholm,4 David B Price1,5

On behalf of the Respiratory Effectiveness Group

1Research in Real-Life, Cambridge, 2Mundesley Medical Centre, Norfolk, 3Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, 4Respiratory Effectiveness Group, Cambridge, 5Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

Purpose: Acute COPD exacerbations account for much of the rising disability and costs associated with COPD, but data on predictive risk factors are limited. The goal of the current study was to develop a robust, clinically based model to predict frequent exacerbation risk.
Patients and methods: Patients identified from the Optimum Patient Care Research Database (OPCRD) with a diagnostic code for COPD and a forced expiratory volume in 1 second/forced vital capacity ratio <0.7 were included in this historical follow-up study if they were ≥40 years old and had data encompassing the year before (predictor year) and year after (outcome year) study index date. The data set contained potential risk factors including demographic, clinical, and comorbid variables. Following univariable analysis, predictors of two or more exacerbations were fed into a stepwise multivariable logistic regression. Sensitivity analyses were conducted for subpopulations of patients without any asthma diagnosis ever and those with questionnaire data on symptoms and smoking pack-years. The full predictive model was validated against 1 year of prospective OPCRD data.
Results: The full data set contained 16,565 patients (53% male, median age 70 years), including 9,393 patients without any recorded asthma and 3,713 patients with questionnaire data. The full model retained eleven variables that significantly predicted two or more exacerbations, of which the number of exacerbations in the preceding year had the strongest association; others included height, age, forced expiratory volume in 1 second, and several comorbid conditions. Significant predictors not previously identified included eosinophilia and COPD Assessment Test score. The predictive ability of the full model (C statistic 0.751) changed little when applied to the validation data set (n=2,713; C statistic 0.735). Results of the sensitivity analyses supported the main findings.
Conclusion: Patients at risk of exacerbation can be identified from routinely available, computerized primary care data. Further study is needed to validate the model in other patient populations.

Keywords: prediction, risk factor, model, validation, FEV1
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study

Carney AS, Price DB, Smith PK, Harvey R, Kritikos V, Bosnic-Anticevich SZ, Christian L, Skinner DA, Carter V, Durieux AMS

Pragmatic and Observational Research 2017, 8:157-165

Published Date: 30 August 2017

Asthma referrals: a key component of asthma management that needs to be addressed

Price D, Bjermer L, Bergin DA, Martinez R

Journal of Asthma and Allergy 2017, 10:209-223

Published Date: 25 July 2017

Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study

Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, Pizzichini MMM, Burden A, Martin J, Price DB

Clinical Epidemiology 2017, 9:231-243

Published Date: 26 April 2017

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study

Voorham J, Vrijens B, van Boven JFM, Ryan D, Miravitlles M, Law LM, Price DB

Pragmatic and Observational Research 2017, 8:31-41

Published Date: 18 April 2017

An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma

Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RMC, Overbeek JA, Khalid JM, van Eickels D, Price DB

Pragmatic and Observational Research 2017, 8:15-30

Published Date: 22 March 2017

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes

Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, Lavorini F, Rodríguez-Roisin R, Ryan D, Wan Yau Ming S, Price DB

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:59-71

Published Date: 21 December 2016

The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, Baldwin M, Jones RC

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2207-2217

Published Date: 15 October 2015

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Postma DS, Roche N, Colice G, Israel E, Martin RJ, van Aalderen WMC, Grigg J, Burden A, Hillyer EV, von Ziegenweidt J, Gopalan G, Price D

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1163-1186

Published Date: 17 October 2014

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:889-905

Published Date: 27 August 2014

Impact of night-time symptoms in COPD: a real-world study in five European countries

Price D, Small M, Milligan G, Higgins V, Garcia Gil E, Estruch J

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:595-603

Published Date: 27 November 2013

Readers of this article also read:

Cytotoxicity and physicochemical characterization of iron–manganese-doped sulfated zirconia nanoparticles [Corrigendum]

Al-Fahdawi MQ, Rasedee A, Al-Qubaisi MS, Alhassan FH, Rosli R, El Zowalaty ME, Naadja SE, Webster TJ, Taufiq-Yap YH

International Journal of Nanomedicine 2015, 10:6657-6658

Published Date: 28 October 2015

Health care and social care costs of pneumonia in Denmark: a register-based study of all citizens and patients with COPD in three municipalities

Brogaard SL, Nielsen MB, Nielsen LU, Albretsen TM, Bundgaard M, Anker N, Appel M, Gustavsen K, Lindkvist RM, Skjoldan A, Breinhild G, Poulsen PB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2303-2309

Published Date: 28 October 2015

Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice

Chen WY, Cheng YH, Hsieh NH, Wu BC, Chou WC, Ho CC, Chen JK, Liao CM, Lin P

International Journal of Nanomedicine 2015, 10:6277-6292

Published Date: 5 October 2015

Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy

Taratula O, Patel M, Schumann C, Naleway MA, Pang AJ, He H, Taratula O

International Journal of Nanomedicine 2015, 10:2347-2362

Published Date: 24 March 2015

Nanopharmaceuticals (part 1): products on the market

Weissig V, Pettinger TK, Murdock N

International Journal of Nanomedicine 2014, 9:4357-4373

Published Date: 15 September 2014